Cerebrovascular Diseases
Original Paper
Cilostazol Improves Outcome after Subarachnoid Hemorrhage: A Preliminary ReportSuzuki S.a · Sayama T.b · Nakamura T.c · Nishimura H.d · Ohta M.c · Inoue T.a · Mannoji H.e · Takeshita I.bDepartments of Neurosurgery,aNippon Steel Yawata Memorial Hospital, bKyushu Rosai Hospital, cShimonoseki City Hospital, and dKyushu Koseinenkin Hospital, Kitakyushu, and eDepartment of Neurosurgery, Yamaguchi Red Cross Hospital, Yamaguchi, Japan
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: October 08, 2010
Accepted: March 03, 2011
Published online: June 11, 2011
Issue release date: July 2011
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 3
ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)
For additional information: https://www.karger.com/CED
Abstract
Background: Cerebral vasospasm (VS) is the most common cause of morbidity and mortality after aneurysmal subarachnoid hemorrhage (SAH). Reversal of VS by intra-arterial infusion of cyclic adenosine monophosphate (cAMP)-elevating agents has been reported; however, the preventive role in the development of VS is not fully understood. This study is designed to evaluate the possible efficacy of using cilostazol, a selective inhibitor of phosphodiesterase type 3 and a cAMP-elevating agent, in patients with SAH. Methods: In this prospective randomized study, we enrolled 100 SAH patients who met the following criteria: neck clipping within 72 h after onset, Hunt and Hess (HH) score ≤4, modified Rankin scale (mRS) score ≤2 prior to ictus, and no serious cardiovascular complications. Patients were divided into control and cilostazol groups; we focused on the effects of cilostazol on the decrease in the incidence of symptomatic VS, cerebral infarction, and the mRS score at discharge. Result: Patients’ age, male/female ratio, mRS score prior to ictus, HH grade, Fisher group, site of the aneurysm, drugs prescribed during the observation period, and length of hospital stay were not different between the groups. Cilostazol did not significantly decrease the incidence of symptomatic VS (37.3% in the control vs. 22.4% in the cilostazol group, p = 0.183) and cerebral infarction (27.5% in control vs. 10.2% in the cilostazol, p = 0.091). However, mRS score was significantly improved at discharge (2.6 in controls vs. 1.5 in the cilostazol group, p = 0.041). Patients’ age being ≤65 years (OR = 8.47, 95% CI = 2.45–29.32, p = 0.0007), Fisher group ≤3 (OR = 4.64, 95% CI = 1.00–21.45, p = 0.049), HH grade ≤2 (OR = 4.31, 95% CI = 1.27–14.59, p = 0.019), no hydrocephalus (OR = 8.55, 95% CI = 1.72–19.23, p = 0.0046), and cilostazol use (OR = 5.52, 95% CI = 1.61–18.90, p = 0.0065) were independent predictors of good outcomes (mRS score ≤2). Conclusion: Cilostazol may improve outcomes after SAH, but further double-blind, placebo-controlled studies are required for a definitive conclusion.
© 2011 S. Karger AG, Basel
Related Articles:
References
- Bederson JB, Connolly ES Jr, Batjer HH, et al, American Heart Association: Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 2009;40:994–1025.
- Rabinstein AA, Lanzino G, Wijdicks EFM: Multidisciplinary management and emerging therapeutic strategies in aneurysmal subarachnoid haemorrhage. Lancet Neurol 2010;9:504–519.
- Suarez JI, Tarr RW, Selman WR: Aneurysmal subarachnoid hemorrhage. N Engl J Med 2006;354:387–396.
- Kaku Y, Yonekawa Y, Tsukahara T, Kazekawa K: Superselective intra-arterial infusion of papaverine for the treatment of cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg 1992;77:842–847.
- Kassell NF, Helm G, Simmons N, Philips CD, Cail WS: Treatment of cerebral vasospasm with intra-arterial papaverine. J Neurosurg 1992;77:848–852.
- Arakawa Y, Kikuta K, Hojo M, Goto Y, Ishii A, Yamagata S: Milrinone for the treatment of cerebral vasospasm after subarachnoid hemorrhage: report of seven cases. Neurosurgery 2001;48:723–730.
- Suzuki S, Ito O, Sayama T, Goto K: Intra- arterial colforsin daropate for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neuroradiology 2010;52:837–845.
- Yoshida K, Watanabe H, Nakamura S: Intraarerial injection of amrinone for vasospasm induced by subarachnoid hemorrhage. Am J Neuroradiol 1997;18:492–496.
-
Goto F, Tohgi H, Hirai S, et al: Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000;9:147–157.
External Resources
- Ito H, Fukunaga M, Suzuki H, et al: Effect of cilostazol on delayed cerebral vasospasm after subarachnoid hemorrhage in rats: evaluation using black blood magnetic resonance imaging. Neurobiol Dis 2008;32:157–161.
- Yamaguchi-Okada M, Nishizawa S, Mizutani A, Namba H: Multifaceted effects of selective inhibitor of phosphodiesterase III, cilostazol, for cerebral vasospasm after subarachnoid hemorrhage in a dog model. Cerebrovasc Dis 2009;28:135–142.
- Yoshimoto T, Shirasaka T, Fujimoto, et al: Cilostazol may prevent cerebral vasospasm following subarachnoid hemorrhage. Neurol Med Chir (Tokyo) 2009;49:235–240.
- Hunt WE, Hess RM: Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg 1968;28:14–20.
- Fisher CM, Kistler JP, Davis JM: Relation cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 1980;6:1–9.
- Shimoda M, Hoshikawa K, Shiramizu H, et al: Early infarction detected by diffusion-weighted imaging in patients with subarachnoid hemorrhage. Acta Neurochir 2010;152:1197–1205.
- Weidauer S, Vatter H, Beck J, et al: Focal laminar cortical infarcts following aneurysmal subarachnoid hemorrhage. Neuroradiology 2008;50:1–8.
- Tanaka K, Gotoh F, Fukuuchi Y, et al: Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke 1989;20:668–673.
- Kasius K, Frijns C, Algra A, et al: Association of platelet and leukocyte counts with delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage. Cerebrovasc Dis 2010;29:576–583.
Article / Publication Details
Received: October 08, 2010
Accepted: March 03, 2011
Published online: June 11, 2011
Issue release date: July 2011
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 3
ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)
For additional information: https://www.karger.com/CED
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
